Efectos del Escitalopram sobre la hiperfosforilación de Tau

REFERENCES

1. Arriagada PV, Growdon JH, Hedley-Whyte ET and Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurology. 1992; 42:631-639.

2. Esmaeli-Azad B, McCarty JH and Feinstein SC. Sense and antisense transfection analysis of tau function: tau influences net microtubule assembly, neurite outgrowth and neuritic stability. J Cell Sci. 1994; 107 :869-879.

3. Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A, DeTure M, Ramsden M, McGowan E, Forster C, Yue M, Orne J, Janus C, Mariash A, Kuskowski M, et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science. 2005; 309:476-481.

4. Zhang Z, Song M, Liu X, Kang SS, Kwon IS, Duong DM, Seyfried NT, Hu WT, Liu Z, Wang JZ, Cheng L, Sun YE, Yu SP, Levey AI and Ye K. Cleavage of tau by asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer’s disease. Nat Med. 2014; 20:1254-1262.

5. Kepe V, Barrio JR, Huang SC, Ercoli L, Siddarth P, Shoghi-Jadid K, Cole GM, Satyamurthy N, Cummings JL, Small GW and Phelps ME. Serotonin 1A receptors in the living brain of Alzheimer’s disease patients. Proc Natl Acad Sci U S A. 2006; 103:702-707.

6. Palmer AM, Francis PT, Benton JS, Sims NR, Mann DM, Neary D, Snowden JS and Bowen DM. Presynaptic serotonergic dysfunction in patients with Alzheimer’s disease. J Neurochem. 1987; 48:8-15.

7. Mowla A, Mosavinasab M, Haghshenas H and Borhani Haghighi A. Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer’s dementia? A double-blind, placebo-controlled clinical trial. J Clin Psychopharmacol. 2007; 27:484-487.

8. Pollock BG, Mulsant BH, Rosen J, Sweet RA, Mazumdar S, Bharucha A, Marin R, Jacob NJ, Huber KA, Kastango KB and Chew ML. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry. 2002; 159:460-465.

9. Porsteinsson AP, Drye LT, Pollock BG, Devanand DP, Frangakis C, Ismail Z, Marano C, Meinert CL, Mintzer JE, Munro CA, Pelton G, Rabins PV, Rosenberg PB, Schneider LS, Shade DM, Weintraub D, et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA. 2014; 311:682-691.

10. Egashira N, Matsumoto Y, Mishima K, Iwasaki K, Fujioka M, Matsushita M, Shoyama Y, Nishimura R and Fujiwara M. Low dose citalopram reverses memory impairment and electroconvulsive shock-induced immobilization. Pharmacol Biochem Behav. 2006; 83:161-167.

11. Lyons L, ElBeltagy M, Bennett G and Wigmore P. Fluoxetine counteracts the cognitive and cellular effects of 5-fluorouracil in the rat hippocampus by a mechanism of prevention rather than recovery. PLoS One. 2012; 7:e30010.

12. Aboukhatwa M, Dosanjh L and Luo Y. Antidepressants are a rational complementary therapy for the treatment of Alzheimer’s disease. Mol Neurodegener. 2010; 5:10.

13. Sheline YI, West T, Yarasheski K, Swarm R, Jasielec MS, Fisher JR, Ficker WD, Yan P, Xiong C, Frederiksen C, Grzelak MV, Chott R, Bateman RJ, Morris JC, Mintun MA, Lee JM, et al. An antidepressant decreases CSF Abeta production in healthy individuals and in transgenic AD mice. Sci Transl Med. 2014; 6:236re234.

14. Ren QG, Wang YJ, Gong WG, Zhou QD, Xu L and Zhang ZJ. Escitalopram Ameliorates Forskolin-Induced Tau Hyperphosphorylation in HEK239/tau441 Cells. J Mol Neurosci. 2015; 56:500-508.

15. Pei JJ, Khatoon S, An WL, Nordlinder M, Tanaka T, Braak H, Tsujio I, Takeda M, Alafuzoff I, Winblad B, Cowburn RF, Grundke-Iqbal I and Iqbal K. Role of protein kinase B in Alzheimer’s neurofibrillary pathology. Acta Neuropathol. 2003; 105:381-392.

16. Beaulieu JM, Zhang X, Rodriguiz RM, Sotnikova TD, Cools MJ, Wetsel WC, Gainetdinov RR and Caron MG. Role of GSK3 beta in behavioral abnormalities induced by serotonin deficiency. Proc Natl Acad Sci U S A. 2008; 105:1333-1338.

17. Sachs BD, Rodriguiz RM, Siesser WB, Kenan A, Royer EL, Jacobsen JP, Wetsel WC and Caron MG. The effects of brain serotonin deficiency on behavioural disinhibition and anxiety-like behaviour following mild early life stress. Int J Neuropsychopharmacol. 2013; 16:2081-2094.

18. Li XH, Zhu W, Roh MS, Friedman AB, Rosborough K and Jope RS. In vivo regulation of glycogen synthase kinase-3beta (GSK3beta) by serotonergic activity in mouse brain. Neuropsychopharmacol. 2004; 29:1426-1431.

19. Barreto RA, Walker FR, Dunkley PR, Day TA and Smith DW. Fluoxetine prevents development of an early stress-related molecular signature in the rat infralimbic medial prefrontal cortex. Implications for depression? BMC Neurosci. 2012; 13:125.

20. Tsai SJ, Liou YJ, Hong CJ, Yu YW and Chen TJ. Glycogen synthase kinase-3beta gene is associated with antidepressant treatment response in Chinese major depressive disorder. Pharmacogenomics J. 2008; 8:384-390.

21. Polter AM, Yang S, Jope RS and Li X. Functional significance of glycogen synthase kinase-3 regulation by serotonin. Cell Signal. 2012; 24:265-271.

22. Shi C, Wu F, Yew DT, Xu J and Zhu Y. Bilobalide prevents apoptosis through activation of the PI3K/Akt pathway in SH-SY5Y cells. Apoptosis. 2010; 15:715-727.